Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.

Precision BioSciences, a US-based genomic medicine developer spun out from Duke University, completed a $110m series B round yesterday that included the institution’s endowment arm Duke Management Company.

Spinout-focused investment firm Osage University Partners also contributed to the round, as did pharmaceutical firms Amgen and EMS, and real estate investment trust Alexandria Real Estate Equities.

Franklin Templeton Investments, Cowen Healthcare Investments, Pontifax AgTech, OCV Partners, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Ridgeback Capital, Agent Capital, VenBio,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?